Avoiding Drug Resistance in HIV Reverse Transcriptase
Open accessThe DOI matches its Crossref record; 305 of the 305 references it cites were found in a registry or an index.
Abstract
HIV reverse transcriptase (RT) is an enzyme that plays a major role in the replication cycle of HIV and has been a key target of anti-HIV drug development efforts. Because of the high genetic diversity of the virus, mutations in RT can impart resistance to various RT inhibitors. As the prevalence of drug resistance mutations is on the rise, it is necessary to design strategies that will lead to drugs less susceptible to resistance. Here we provide an in-depth review of HIV reverse transcriptase, current RT inhibitors, novel RT inhibitors, and mechanisms of drug resistance. We also present novel strategies that can be useful to overcome RT's ability to escape therapies through drug resistance. While resistance may not be completely avoidable, designing drugs based on the strategies and principles discussed in this review could decrease the prevalence of drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Resistance to them mainly arises from the high error rate of HIV reverse transcriptase (RT) during replication. The key resistance mechanisms involve either excision, where a mutated RT removes an incorporated NRTI, or discrimination, where mutations alter the dNTP-binding pocket to selectively block NRTI-triphosphate incorporation (4, 40).”
From Research progress on HIV-1 structural proteins and antiviral therapies (2026) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“NNRTIs inhibit HIV-1 reverse transcriptase (RT) by binding to a specific, non-catalytic hydrophobic pocket known as the non-nucleoside inhibitor binding pocket (NNIBP). This binding site is located approximately 10 Å from the polymerase active site. The interaction induces conformational changes in RT that disrupt its enzymatic function, thereby inhibiting viral DNA synthesis (40, 45).”
From Research progress on HIV-1 structural proteins and antiviral therapies (2026) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–305 of 305
Most Retroviral Recombinations Occur during Minus-Strand DNA Synthesis
Zhang, J., Tang, L., Li, T., Ma, Y., & Sapp, C. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.5.2313-2322.2000 · Cited by 69
Esposito, F., & Tramontano, E. (2014) · Antiviral Chemistry and Chemotherapy · doi:10.3851/imp2690 · Cited by 68
Biochemical Mechanism of HIV-1 Resistance to Rilpivirine
Singh, K., Marchand, B., Rai, D. K., Sharma, B., Michailidis, E., Ryan, E. M., Matzek, K. B., Leslie, M. D., Hagedorn, A. N., Li, Z., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.398180 · Cited by 68
Self-citationRole of Residues in the Tryptophan Repeat Motif for HIV-1 Reverse Transcriptase Dimerization
Tachedjian, G., Aronson, H. G., Santos, M. D. L., Seehra, J., McCoy, J. M., & Goff, S. P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01433-x · Cited by 67
Lanchy, J.-M., Keith, G., Grice, S. F. J. L., Ehresmann, B., Ehresmann, C., & Marquet, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.38.24425 · Cited by 66
Kankanala, J., Kirby, K. A., Liu, F., Miller, L., Nagy, E., Wilson, D. J., Parniak, M. A., Sarafianos, S. G., & Wang, Z. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00465 · Cited by 66
Self-citationMutations in the central polypurine tract of HIV-1 result in delayed replication
Hungnesi, O., Tjøtta, E., & Grinde, B. (1992) · Virology · doi:10.1016/0042-6822(92)91230-r · Cited by 65
Rates of transmission of antiretroviral drug resistant strains of HIV-1
Ammaranond, P., Cunningham, P., Oelrichs, R. B., Suzuki, K., Harris, C., Leas, L., Grulich, A. E., Cooper, D. A., & Kelleher, A. D. (2003) · Journal of Clinical Virology · doi:10.1016/s1386-6532(02)00114-2 · Cited by 64
van Wamel, J. L. B., & Berkhout, B. (1998) · Virology · doi:10.1006/viro.1998.9096 · Cited by 63
Structure of the genome of moloney murine leukemia virus: a terminally redundant sequence
Coffin, J. M., Hageman, T. C., Maxam, A. M., & Haseltine, W. A. (1978) · Cell · doi:10.1016/0092-8674(78)90226-x · Cited by 62
Resistance to antiretroviral drugs in patients with primary HIV-1 infection
BRENNER, B. G., Wainberg, M. A., Salomón, H., Rouleau, D., Dascal, A., Spira, B., Sékaly, R., Conway, B., & Routy, J. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00270-3 · Cited by 61
Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus
Tramontano, E., Corona, A., & Menéndez‐Arias, L. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104613 · Cited by 61
Tambuyzer, L., Vingerhoets, J., Azijn, H., Daems, B., Nijs, S., de Béthune, M., & Picchio, G. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2009.0302 · Cited by 60
Terminal redundancy and the origin of replication of Rous sarcoma virus RNA.
Coffin, J. M., & Haseltine, W. A. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.5.1908 · Cited by 60
Götte, M., Maier, G., Gross, H. J., & Heumann, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.17.10139 · Cited by 60
Meyer, P. R., Lennerstrand, J., Matsuura, S. E., Larder, B. A., & Scott, W. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.6.3871-3877.2003 · Cited by 60
Garcia-Lerma, J. G., MacInnes, H., Bennett, D., Weinstock, H., & Heneine, W. (2004) · Journal of Virology · doi:10.1128/jvi.78.14.7545-7552.2004 · Cited by 60
Reuman, E. C., Rhee, S., Holmes, S., & Shafer, R. W. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq140 · Cited by 60
Boyer, P. L., Sarafianos, S. G., Arnold, E., & Hughes, S. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3056 · Cited by 59
Self-citationRilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants
Smith, S. J., Pauly, G. T., Akram, A., Melody, K., Ambrose, Z., Schneider, J. P., & Hughes, S. H. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001031 · Cited by 59
Zhang, Z., Xu, W. F., Koh, Y., Shim, J. H., Girardet, J., Yeh, L., Hamatake, R. K., & Hong, Z. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01032-06 · Cited by 58
Design of Mutation‐resistant HIV Protease Inhibitors with the Substrate Envelope Hypothesis
Chellappan, S., Reddy, G. S., Ali, A., Nalam, M. N. L., Anjum, S. G., Cao, H., Kairys, V., Fernandes, M. X., Altman, M. D., Tidor, B., et al. (2007) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00514.x · Cited by 57
Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
Chong, P. Y., Sebahar, P. R., Youngman, M., Garrido, D. M., Zhang, H., Stewart, E. L., Nolte, R. T., Wang, L., Ferris, R. G., EDELSTEIN, M. P., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301294g · Cited by 56
Chan, A. H., Lee, W., Spasov, K. A., Cisneros, J. A., Kudalkar, S. N., Petrova, Z. O., Buckingham, A. B., Anderson, K. S., & Jorgensen, W. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711463114 · Cited by 56
The HIV-1 Central Polypurine Tract Functions as a Second Line of Defense against APOBEC3G/F
Hu, C., Saenz, D. T., Fadel, H. J., Walker, W., Peretz, M., & Poeschla, E. M. (2010) · Journal of Virology · doi:10.1128/jvi.00723-10 · Cited by 55
Basson, A. E., Rhee, S., Parry, C. M., El‐Khatib, Z., Charalambous, S., de Oliveira, T., Pillay, D., Hoffmann, C. J., Katzenstein, D. A., Shafer, R. W., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04215-14 · Cited by 55
Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity
Ilina, T., LaBarge, K., Sarafianos, S. G., Ishima, R., & Parniak, M. A. (2012) · Biology · doi:10.3390/biology1030521 · Cited by 54
Self-citationGupta, S., Fransen, S., Paxinos, E. E., Stawiski, E. W., Huang, W., & Petropoulos, C. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00870-09 · Cited by 54
Pari, K., Mueller, G. A., DeRose, E. F., Kirby, T. W., & London, R. E. (2003) · Biochemistry · doi:10.1021/bi0204894 · Cited by 53
Sarafianos, S. G., Hughes, S. H., & Arnold, E. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.02.027 · Cited by 52
Self-citationMurphey‐Corb, M., Rajakumar, P. A., Michael, H., Nyaundi, J., Didier, P. J., Reeve, A. B., Mitsuya, H., Sarafianos, S. G., & Parniak, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00723-12 · Cited by 52
Self-citationIdentification of a preferred region for recombination and mutation in HIV-1 gag
Dykes, C., Balakrishnan, M., Planelles, V., Zhu, Y., Bambara, R. A., & Demeter, L. M. (2004) · Virology · doi:10.1016/j.virol.2004.02.033 · Cited by 51
Cowan, J. A., Ohyama, T., Howard, K., Rausch, J. W., Cowan, S. M. L., & Le Grice, S. F. J. (2000) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s007750050009 · Cited by 51
Takamatsu, Y., Tanaka, Y., Kohgo, S., Murakami, S., Singh, K., Das, D., Venzon, D. J., Amano, M., Higashi‐Kuwata, N., Aoki, M., et al. (2015) · Hepatology · doi:10.1002/hep.27962 · Cited by 51
Self-citationWang, X., Gao, P., Menéndez‐Arias, L., Liu, X., & Zhan, P. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170113110839 · Cited by 51
Elsulfavirine: First Global Approval
Al-Salama, Z. T. (2017) · Drugs · doi:10.1007/s40265-017-0820-3 · Cited by 51
Schauer, G. D., Huber, K. D., Leuba, S. H., & Sluis‐Cremer, N. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku819 · Cited by 47
Ehteshami, M., Scarth, B. J., Tchesnokov, E. P., Dash, C., Grice, S. F. J. L., Hallenberger, S., Jochmans, D., & Götte, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804882200 · Cited by 46
Schuckmann, M. M., Marchand, B., Hachiya, A., Kodama, E. N., Kirby, K. A., Singh, K., & Sarafianos, S. G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.153783 · Cited by 46
Self-citationKankanala, J., Kirby, K. A., Huber, A. D., Casey, M. C., Wilson, D. J., Sarafianos, S. G., & Wang, Z. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.054 · Cited by 46
Self-citationParkin, N. T., Gupta, S., Chappey, C., & Petropoulos, C. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.351-354.2006 · Cited by 45
Molecular determinants of HIV-1 intersubtype recombination potential
Chin, M. P. S., Chen, J., Nikolaitchik, O. A., & Hu, W.-S. (2007) · Virology · doi:10.1016/j.virol.2007.01.034 · Cited by 44
Vernekar, S. K. V., Tang, J. Y., Wu, B., Huber, A. D., Casey, M. C., Myshakina, N. S., Wilson, D. J., Kankanala, J., Kirby, K. A., Parniak, M. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00440 · Cited by 44
Self-citationKirby, K. A., Michailidis, E., Fetterly, T. L., Steinbach, M., Singh, K., Marchand, B., Leslie, M. D., Hagedorn, A. N., Kodama, E. N., Márquez, V. E., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01703-13 · Cited by 44
Self-citationJeeninga, R. E., Keulen, W., Boucher, C. A., Sanders, R. W., & Berkhout, B. (2001) · Virology · doi:10.1006/viro.2001.0888 · Cited by 44
Markowitz, M. H., Gettie, A., Bernard, L. S., Andrews, C. D., Mohri, H., Horowitz, A., Grasperge, B. F., Blanchard, J., Niu, T., Sun, L. Z., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz271 · Cited by 44
Balzarini, J. M., Pelemans, H., Esnouf, R. M., & Clercq, E. D. (1998) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1998.14.255 · Cited by 43
Wang, L., Sarafianos, S. G., & Wang, Z. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00450 · Cited by 43
Self-citationEmerging reverse transcriptase inhibitors for HIV-1 infection
Mohammad, A., Pannek, S., & Fichtenbaum, C. J. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1474202 · Cited by 42
Özen, A., Sherman, W., & Schiffer, C. A. (2013) · Journal of Chemical Theory and Computation · doi:10.1021/ct400603p · Cited by 40
HIV resistance to zidovudine: the role of pyrophosphorolysis
Arion, D., & Parniak, M. A. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0076 · Cited by 39
Russell, J. W., & Klunk, L. J. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90176-7 · Cited by 39
Stone, C., Ait‐Khaled, M., Craig, C., Griffin, P. C., & Tisdale, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1413-1415.2004 · Cited by 39
August, E. M., Marongiu, M. E., Tai-Shun, L., & Prusoff, W. H. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90655-7 · Cited by 38
Identification of a Transmission Chain of HIV Type 1 Containing Drug Resistance-Associated Mutations
Taylor, S. R., Cane, P., Hué, S., Xu, L., Wrin, T., Lie, Y., Hellmann, N. S., Petropoulos, C. J., Workman, J., Ratcliffe, D., et al. (2003) · AIDS Research and Human Retroviruses · doi:10.1089/088922203765551700 · Cited by 38
Cristofaro, J. V., Rausch, J. W., Grice, S. F. J. L., & DeStefano, J. J. (2002) · Biochemistry · doi:10.1021/bi025871v · Cited by 38
Johnson, B. C., Pauly, G. T., Rai, G., Patel, D., Bauman, J. D., Baker, H. L., Das, K., Schneider, J. P., Maloney, D. J., Arnold, E., et al. (2012) · Retrovirology · doi:10.1186/1742-4690-9-99 · Cited by 36
Deng, N., Hoyte, A., Mansour, Y. E., Mohamed, M. S., Fuchs, J. R., Engelman, A. N., Kvaratskhelia, M., & Levy, R. (2016) · Protein Science · doi:10.1002/pro.2997 · Cited by 36
Recent progress in the research of small molecule HIV-1 RNase H inhibitors
Cao, L., Song, W., Clercq, E., Zhan, P., & Liu, X. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140120121158 · Cited by 34
Yu, F., Wen, Y., Wang, J., Gong, Y.-R., Feng, K., Ye, R., Jiang, Y., Zhao, Q., Pan, P., Wu, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19783-3 · Cited by 33
Wang, L., Tang, J. Y., Huber, A. D., Casey, M. C., Kirby, K. A., Wilson, D. J., Kankanala, J., Parniak, M. A., Sarafianos, S. G., & Wang, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.035 · Cited by 32
Self-citationMulky, A., Sarafianos, S. G., Jia, Y., Arnold, E., & Kappes, J. C. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.03.057 · Cited by 31
Self-citationAchuthan, V., Keith, B. J., Connolly, B. A., & DeStefano, J. J. (2014) · Journal of Virology · doi:10.1128/jvi.00752-14 · Cited by 31
Small Molecule Inhibitors Targeting HIV‐1 Reverse Transcriptase Dimerization
Grohmann, D., Corradi, V., Elbasyouny, M., Baude, A., Horenkamp, F. A., Laufer, S. D., Manetti, F., Botta, M., & Restle, T. (2008) · ChemBioChem · doi:10.1002/cbic.200700669 · Cited by 30
Boyer, P. L., Imamichi, T., Sarafianos, S. G., Arnold, E., & Hughes, S. H. (2004) · Journal of Virology · doi:10.1128/jvi.78.18.9987-9997.2004 · Cited by 30
Self-citationPham, H. T., Xiao, M. A., Principe, M. A. V., Wong, A., & Mésplède, T. (2020) · Drugs in Context · doi:10.7573/dic.2019-11-4 · Cited by 30
Design, Conformation, and Crystallography of 2-Naphthyl Phenyl Ethers as Potent Anti-HIV Agents
Lee, W., Chan, A. H., Spasov, K. A., Anderson, K. S., & Jorgensen, W. L. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00390 · Cited by 29
Kirby, K. A., Singh, K., Michailidis, E., Marchand, B., Kodama, E. N., Ashida, N., Mitsuya, H., Parniak, M. A., & Sarafianos, S. G. (2011) · PubMed · Cited by 28
Self-citationLy, J. K., Margot, N., MacArthur, H. L., Hung, M., Miller, M. D., & White, K. (2007) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020701800603 · Cited by 28
Iglesias, M. C., Ringeard, M., Nunzio, F. D., Fernandez, J., Gaudin, R., Souque, P., Charneau, P., & Arhel, N. J. (2011) · Retrovirology · doi:10.1186/1742-4690-8-92 · Cited by 26
A Comparison of the Phenotypic Susceptibility Profiles of Emtricitabine and Lamivudine
Borroto–Esoda, K., Parkin, N. T., & Miller, M. D. (2007) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020701800505 · Cited by 26
Hachiya, A., Reeve, A. B., Marchand, B., Michailidis, E., Ong, Y. T., Kirby, K. A., Leslie, M. D., Oka, S., Kodama, E. N., Rohan, L. C., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00283-13 · Cited by 25
Self-citationHung, M., Tokarsky, E. J., Lagpacan, L., Zhang, L., Suo, Z., & Lansdon, E. B. (2019) · Communications Biology · doi:10.1038/s42003-019-0706-x · Cited by 25
La, J., Latham, C. F., Tinetti, R. N., Johnson, A., Tyssen, D. P., Huber, K. D., Sluis‐Cremer, N., Simpson, J. S., Headey, S. J., Chalmers, D. K., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423900112 · Cited by 24
Eshleman, S. H., Jones, D. C., Galovich, J., Paxinos, E. E., Petropoulos, C. J., Jackson, J. B., & Parkin, N. T. (2006) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2006.22.289 · Cited by 24
Fragment Screening and HIV Therapeutics
Bauman, J. D., Patel, D., & Arnold, E. (2011) · Topics in current chemistry · doi:10.1007/128_2011_232 · Cited by 24
Gregson, J., Rhee, S. Y., Datir, R., Pillay, D., Perno, C. F., Derache, A., Shafer, R. S., & Gupta, R. K. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz631 · Cited by 24
Das, K., Martinez, S. E., & Arnold, E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00224-17 · Cited by 24
Balamane, M., Varghese, V., Melikian, G., Fessel, W. J., Katzenstein, D. A., & Shafer, R. W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00648-12 · Cited by 23
Ruiz, F. X., Hoang, A., Das, K., & Arnold, E. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01289 · Cited by 23
Kirk, O., Pedersen, C., Law, M. G., Gulick, R. M., Moyle, G. J., Montaner, J., Eron, J. J., Phillips, A. N., & Lundgren, J. D. (2002) · Antiviral Therapy · doi:10.1177/135965350200700407 · Cited by 22
Inhibition of HIV‐1 Reverse Transcriptase Dimerization by Small Molecules
Tintori, C., Corona, A., Esposito, F., Brai, A., Grandi, N., Ceresola, E. R., Clementi, M., Canducci, F., Tramontano, E., & Botta, M. (2016) · ChemBioChem · doi:10.1002/cbic.201500668 · Cited by 22
Kirby, K. A., Myshakina, N. S., Christen, M. T., Chen, Y.-L., Schmidt, H. A., Huber, A. D., Xi, Z., Kim, S., Rao, R. K., Kramer, S. T., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01351-17 · Cited by 22
Self-citationPre-exposure Prophylaxis for Human Immunodeficiency Virus
Castel, A. D., Magnus, M., & Greenberg, A. E. (2014) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.08.001 · Cited by 21
Host RNA polymerase II makes minimal contributions to retroviral frame-shift mutations
Zhang, J. (2004) · Journal of General Virology · doi:10.1099/vir.0.80081-0 · Cited by 20
Zhang, W., Parniak, M. A., Sarafianos, S. G., Empey, P. E., & Rohan, L. C. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.03.022 · Cited by 17
Self-citationPre-Exposure Prophylaxis for HIV: Evidence and Perspectives
Nikolopoulos, G. K., Christaki, E., Paraskevis, D. N., & Bonovas, S. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170329145053 · Cited by 17
Higashi‐Kuwata, N., Hayashi, S., Das, D., Kohgo, S., Murakami, S., Hattori, S.-I., Imoto, S., Venzon, D. J., Singh, K., Sarafianos, S. G., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02143-18 · Cited by 17
Self-citationHIV-1 M184V reverse transcriptase-DNA complex with (-)-FTC-TP
Lansdon, E. B. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6uir/pdb · Cited by 17
Theys, K., Camacho, R. J., Gómes, P., Vandamme, A., & Rhee, S. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.02.011 · Cited by 15
Intracellular Pharmacology of Emtricitabine and Tenofovir
Stevens, R. C., Blum, M. R., Rousseau, F. S., & Kearney, B. P. (2004) · Clinical Infectious Diseases · doi:10.1086/423810 · Cited by 14
Achuthan, V., & DeStefano, J. J. (2015) · BMC Biochemistry · doi:10.1186/s12858-015-0041-x · Cited by 13
Determinants of Active-Site Inhibitor Interaction with HIV-1 RNase H
Xi, Z., Wang, Z., Sarafianos, S. G., Myshakina, N. S., & Ishima, R. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00300 · Cited by 13
Self-citationYu, Q., & Morrow, C. D. (1999) · Virology · doi:10.1006/viro.1998.9542 · Cited by 11
Kulkarni, R., Feng, J. Y., Miller, M. D., & White, K. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.11.010 · Cited by 11
Highly Active Antiretroviral Therapy (HAART)
Templeton, D. M., Schwenk, M., Klein, R., & Duffus, J. H. (2016) · IUPAC Standards Online · doi:10.1515/iupac.84.0635 · Cited by 11
Scott, W. A. (2011) · Viruses · doi:10.3390/v3010020 · Cited by 9
Han, Q., Sarafianos, S. G., Arnold, E., Parniak, M. A., Gaffney, B. L., & Jones, R. A. (2007) · Organic Letters · doi:10.1021/ol7023746 · Cited by 9
Self-citationAdherence, resistance, and timing: current issues in the use of new therapies.
Volberding, P. A. (2002) · PubMed · Cited by 9
Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality
Pinto, A. N., Grey, P., Shaik, A., Cooper, D. A., Kelleher, A. D., & Petoumenos, K. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2017.0284 · Cited by 8
Yasutake, Y., Hattori, S.-I., Tamura, N., Matsuda, K., Kohgo, S., Maeda, K., & Mitsuya, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.026 · Cited by 8
Xu, H., Colby-Germinario, S. P., Quashie, P. K., Bethell, R. C., & Wainberg, M. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00315-15 · Cited by 7
Hashimoto, M., Taguchi, K., Ishiguro, T., Kohgo, S., Imoto, S., Yamasaki, K., Mitsuya, H., & Otagiri, M. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12897 · Cited by 4
Cilento, M. E., Kirby, K. A., Tedbury, P. R., & Sarafianos, S. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21570-7 · Cited by 2
Self-citationThe art and practice of structure-based drug design: A molecular modeling perspective
(1996) · doi:10.1002/(sici)1098-1128(199601)16:1<3::aid-med1>3.0.co;2-6
Research works printed but not linked: 8
- Vogt V., 1997, Retroviruses
- Telesnitsky A., 1997, Retroviruses
- Volberding P., 2002, AIDS Read., 12, 349
- D’Aquila R. T., 2003, Top HIV Med., 11, 92
- Kirby K. A., 2011, Cell. Mol. Biol., 57, 40
- Grobler, J. A.; Fillgrove, K.; Hazuda, D.; Huang, Q.; Lai, M. T.; Matthews, R. P.; Rudd, D. J.; Vargo, R. MK-8591 potency and PK provide high inhibitory quotients at low doses QD and QW. In Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA , 2019; 481, http://www.croiconference.org/sessions/mk-8591-potency-and-pk-provide-high-inhibitory-quotients-low-doses-qd-and-qw (accessed 2020-07-13).
- Bekker, L-G.; Li, S. S.; Tolly, B.; Marzinke, M. A.; Mgodi, N.; Justman, J. E.; Swaminathan, S.; Adeyeye, A.; Farrior, J. H.; Sista, N. Hptn 076:Tmc278 ls safe, tolarable, and acceptable for HIV preexposure prophylaxis. In Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA , 2017.
- 2011, Janssen Products
Cited by
Recent Advances in Pyrimidine-Based Drugs
Nammalwar, B., & Bunce, R. A. (2024) · Pharmaceuticals · doi:10.3390/ph17010104 · Cited by 192
Approved HIV reverse transcriptase inhibitors in the past decade
Li, G., Wang, Y., & Clercq, E. D. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.009 · Cited by 144
Xue, Y., Liu, C., Andrews, G., Wang, J., & Ge, Y. (2022) · Nano Convergence · doi:10.1186/s40580-022-00307-9 · Cited by 115
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective
Carr, A., Mackie, N., Paredes, R., & Ruxrungtham, K. (2023) · Antiviral Therapy · doi:10.1177/13596535231201162 · Cited by 89
“1,17,18 The high replication rate, error-prone reverse transcription and high recombination rate of HIV give rise to a genetically diverse, heterogeneous virus population that is distributed as a quasispecies.”
BackgroundInfluentialWang, Z., Cherukupalli, S., Xie, M., Wang, W., Jiang, X., Jia, R., Pannecouque, C. C., Clercq, E. D., Kang, D., Zhan, P., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01758 · Cited by 78
Metadata
- Authors
- Cilento, M. E., Kirby, K. A., & Sarafianos, S. G.
- Affiliations
- Emory University (US)
- Corresponding author
- Sarafianos, Stefan G.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-01-28
- Volume
- 121
- Issue
- 6
- Pages
- 3271-3296
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- PMC
- PMC8149104
- OpenAlex
- W3125954347
- Cited by
- 106
- References
- 305
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 27 · 2023: 17 · 2022: 18 · 2021: 7
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01 AI121315, R37 AI076119, U54 AI150472)
- National Institute of General Medical Sciences (R01 GM118012, T32 GM008367)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- HIV reverse transcriptase, drug resistance, reverse transcriptase inhibitors, resistance mutations, HIV drug development, antiretroviral therapy
- MeSH terms
- Humans, Models, Molecular, Mutation, Protein Binding, Protein Conformation, Structure-Activity Relationship, Virus Replication, Drug Design, Signal Transduction, HIV-1, HIV Infections, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Drug Resistance, Viral, HIV Reverse Transcriptase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.